Clinical trials: Solid Malignant Tumors
Solid Tumor, Meningeal Metastasis
Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors
This is an open, single-arm, single-center, interventional clinical study. It is planned to enroll 3-6 patients with meningeal metastases from B7H3+ solid tumors and to explore, on a small scale, the efficacy of local injection…
- Trial name
- NCT06592092
- Testing
- QH104 Cell injection
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
Previous research has demonstrated that investigators can coat (arm) T cells with a special molecule called GD2 bispecific antibody that will help T cells recognize neuroblastoma and osteosarcoma cells and kill them.
- Trial name
- NCT02173093
- Testing
- IL-2, GD2Bi-aATC, GM-CSF
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Advanced Solid Tumors
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1.
- Trial name
- NIMBLe (NCT03461952)
- Testing
- Nivolumab, Ipilimumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 4 people
- Sponsor
- Canadian Cancer Trials Group
Solid Tumor, Adult
PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor
In this single-center,open-label, phase I study, the safety and efficacy of PIN in combination with programmed cell death protein antibody (anti-PD1) therapeutic regimen will be evaluated in patients with late-stage advanced…
- Trial name
- NCT06883149
- Testing
- PIN +anti-PD1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese PLA General Hospital
Lung Cancer, Solid Pulmonary Nodules
Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features.
Study Objective: To comprehensively analyze the preoperative clinical and imaging characteristics of solid pulmonary nodules, investigate the risk factors associated with malignant solid pulmonary nodules, and provide a reference…
- Conditions
- Lung Cancer, Solid Pulmonary Nodules, Pulmonary Nodules
- Trial name
- NCT06685458
- Testing
- Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling
- Volunteers
- 320 people
- Sponsor
- The Third Affiliated Hospital of Kunming Medical College.
Solid Tumors, Hematologic Malignancies
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors.
- Conditions
- Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
- Trial name
- NCT00741234
- Testing
- SB939, Azacitidine
- Where
- 5 sites in United States, Singapore
- Volunteers
- 85 people
- Sponsor
- S*BIO
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, capecitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084734
- Testing
- capecitabine, cisplatin, docetaxel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumor
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
This is a multicenter, open-label Phase 1 trial to investigate the safety, PK, and pharmacodynamics of the Polθ inhibitor RP-3467 alone or in combination with the poly-ADP ribose polymerase inhibitor (PARPi) olaparib in adults…
- Trial name
- POLAR (NCT06560632)
- Testing
- RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Repare Therapeutics
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors
This is an open-label, single-arm phase I dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of MT027 in patients with advanced primary peritoneal malignancies…
- Trial name
- NCT06912152
- Testing
- MT027 CAR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhejiang University
Advanced Solid Tumor
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-XT117 injection in patients with FAP-positive advanced solid tumors.
- Trial name
- NCT06211647
- Testing
- [177Lu]Lu-XT117
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruimin Wang
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
Advanced Solid Tumors or Hematologic Malignancies
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
APG-1387 is a potent, bivalent small-molecule Inhibitor of Apoptosis Protein (IAP) antagonist. APG-1387 has shown strong dose- and schedule-dependent antitumor activities in multiple human cancer xenograft models, APG-1387 also…
- Trial name
- NCT03386526
- Testing
- APG-1387 for Injection
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as well as in combination with Investigator's choice of nivolumab or…
- Trial name
- NCT05901285
- Testing
- VAX014, Nivolumab or pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vaxiion Therapeutics
Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Remote Monitoring in Cancer Care: A Platform Study
This study investigates a device that closely monitors vital signs, as well as a smartphone application (app) that allows patients to respond to different questions and tests that will monitor for new symptoms.
- Conditions
- Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Digestive System Neoplasm
- Trial name
- NCT05018208
- Testing
- Computer-Assisted Intervention, Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
KRAS G12C
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Phase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925.
- Trial name
- NCT05005234
- Testing
- GFH925
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Cancer, Solid Tumors
Gemcitabine and Dasatinib in Advanced Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of dasatinib in combination with gemcitabine that can be given to patients with advanced solid tumors.
- Trial name
- NCT00429234
- Testing
- Dasatinib, Gemcitabine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Solid Tumor
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.
- Trial name
- NCT06375564
- Testing
- 177Lu-AB-3PRGD2 radioligand therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University